NCT06065800 (STEADY) is a clinical trial of STEELEX® Sternum Set in Sternum Closure, sponsored by Aesculap AG.

Who is sponsoring NCT06065800?

NCT06065800 is sponsored by Aesculap AG.

What drugs are being tested in NCT06065800?

Interventions in NCT06065800: STEELEX® Sternum Set.

What condition does NCT06065800 study?

NCT06065800 studies Sternum Closure.

Is NCT06065800 still recruiting?

NCT06065800 is currently completed. Last updated 17 November 2025.

Last reviewed 2025-11-17 · How we verify

NCT06065800: STEADY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

STEELEX® Sternum Set + BONE WAX® + STEELEX® Electrode Set in Patients Undergoing Cardiac Surgery

Completed Last updated 17 November 2025

What this trial tests

trial testing STEELEX® Sternum Set in Sternum Closure in 150 participants. Completed in 11 April 2025.

Timeline

17 May 2023

Primary endpoint
13 November 2024

11 April 2025

Quick facts

Lead sponsor	Aesculap AG
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150
Start date	17 May 2023
Primary completion	13 November 2024
Estimated completion	11 April 2025
Sites	1 location across Spain

Drugs / interventions tested

STEELEX® Sternum Set

Conditions studied

Sternum Closure — all drugs for Sternum Closure →

Sponsor

Aesculap AG — full company profile →

Who can join

18 and older, any sex, with Sternum Closure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to assess the effectiveness and performance of using STEELEX® Sternum Set, BONE WAX® and STEELEX® Electrode Set in patients undergoing cardiac surgery. The primary endpoint is the assessment of STEELEX® Sternum Set effectiveness for sternal healing at month 1 ± 1 week post-surgery. This study is designed as a prospective, non-interventional, single center, Post Market Clinical Follow-Up cohort study. The products under investigation will be used in routine clinical practice and according to the instructions of use. No diagnostic or therapeutic intervention outside of routine clinical practice will be applied, and all study visits will coincide with those that will be scheduled for routine follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Aesculap AG trials

Trials by the same sponsor.

NCT05441618 — Post Market Clinical Follow-Up Study on the Performance and Safety of Lyoplant® · completed
NCT05944081 — Postmarket Clinical Follow-Up Study on Arcadius XP L® Interbody Fusion Device · withdrawn
NCT06298500 — Clinical Performance of HISTOACRYL® LAPFIX - CANNULA for Laparoscopic Inguinal Hernia Repair · completed
NCT06055946 — Symmcora® Long-term Bidirectional Barbed Suture for Anastomosis in Patients Undergoing Robot Assisted Radical Prostatect · completed
NCT05182320 — Study Measuring the Effects of Patient Data for Total Hip and Total Knee Arthroplasty Patients Using an APP Based Sensor · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06065800 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aesculap AG
Last refreshed: 17 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06065800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing